November 23, 2016 - By Nellie Frank
In a a research note revealed to investors and clients on 23 November, FBR & Co. has downgraded Juno Therapeutics (NASDAQ:JUNO) stock to a Mkt Perform and has set an estimated 12-month target price at $30.0. JUNO’s old rating was Outperform.
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. $73 is the highest target while $39 is the lowest. The $51.80 average target is 137.94% above today’s ($21.77) stock price. Juno Therapeutics Inc has been the topic of 18 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The rating was initiated by Northland Capital on Wednesday, July 22 with “Outperform”. The company was initiated on Friday, January 29 by Suntrust Robinson. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Buy” rating by Standpoint Research on Tuesday, December 15. On Friday, July 8 the stock rating was maintained by FBR Capital with “Outperform”. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Outperform” rating by FBR Capital on Tuesday, August 18. Maxim Group maintained Juno Therapeutics Inc (NASDAQ:JUNO) on Friday, August 5 with “Buy” rating. Raymond James initiated the stock with “Outperform” rating in Thursday, June 2 report. As per Monday, August 24, the company rating was initiated by Standpoint Research. Goldman Sachs initiated the shares of JUNO in a report on Wednesday, November 18 with “Neutral” rating. The rating was downgraded by JP Morgan to “Neutral” on Friday, July 8.
About 14.20 million shares traded hands or 879.31% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 32.60% since April 21, 2016 and is downtrending. It has underperformed by 37.93% the S&P500.
Insitutional Activity: The institutional sentiment increased to 1.4 in Q2 2016. Its up 0.06, from 1.34 in 2016Q1. The ratio increased, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
The Florida-based Ladenburg Thalmann Serv Inc has invested 0% in Juno Therapeutics Inc (NASDAQ:JUNO). Great West Life Assurance Can reported 4,718 shares or 0% of all its holdings. Tower Rech Capital Ltd Limited Liability Company (Trc) holds 0% or 70 shares in its portfolio. Ibm Retirement Fund accumulated 0.01% or 6,342 shares. Boyer Corporon Wealth Mgmt Ltd Com holds 12,579 shares or 0.23% of its portfolio. Shell Asset Mgmt holds 11,697 shares or 0.01% of its portfolio. Price T Rowe Md, a Maryland-based fund reported 23,600 shares. Point72 Asia (Hong Kong) Ltd accumulated 0% or 100 shares. California Public Employees Retirement Sys holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 79,500 shares. Blackrock Invest Ltd Liability last reported 25,315 shares in the company. Dekabank Deutsche Girozentrale last reported 0.03% of its portfolio in the stock. Mitsubishi Ufj Trust & Bk holds 0.08% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 959,230 shares. Blackrock Fund Advsrs has 0.02% invested in the company for 1.96M shares. Moreover, Da Davidson & has 0.01% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 12,018 shares. Global X Mgmt Co Ltd Liability Co has invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO).
Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $2.19 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
More recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fortune.com which released: “Juno Therapeutics: Shares Sink After More Drug Trial Deaths” on November 23, 2016. Also Marketwatch.com published the news titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …” on November 23, 2016. Fool.com‘s news article titled: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” with publication date: November 03, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank